Croatia’s multiple myeloma bill rose fast as treatment and productivity costs climbed
Croatia’s multiple myeloma burden has moved well beyond the hematology clinic and into national budgeting. A whole-of-government fiscal analysis found that the disease’s total annual cost rose from €9.37 million in 2009 to €44.99 million in 2024, while the projected burden reaches €60.30 million by 2030 if current trends continue.
The numbers point to a disease that is no longer expensive only because of drug acquisition or hospital care. The fiscal drag now extends into tax revenues, work absence, disability, and caregiver time, which means the economic consequences spread across ministries and social systems rather than staying inside the health insurance ledger.
Direct medical spending now dominates the burden
Investigators used administrative data on incidence, mortality, treatment expenditure, sick leave, disability, and macroeconomic indicators to estimate both direct and indirect fiscal effects. Health care costs were measured as gross reimbursement expenditures from the Croatian Health Insurance Fund before confidential rebates, and the fiscal model projected the 2009-2024 series forward linearly to 2030.
The direct spending share grew steadily over time. In 2009, health care accounted for 76% of total costs; by 2024, that share had climbed to 89%. Under the status-quo projection, direct medical costs would still represent 84% of the 2030 total. The shift is clinically familiar: as more patients live longer with multiple myeloma, they are exposed to repeated lines of therapy, monitoring, supportive care, and complications management, each of which adds cost even when survival improves.
A rising prevalence of treated disease can make success look expensive on paper.
Per prevalent patient, the annual fiscal burden increased from €7,319 in 2009 to €19,689 in 2024. That rise matters because it reframes the disease from a rare hematologic diagnosis into a persistent system-level expense. The increase per patient suggests that the economic pressure is being amplified not only by more patients living with the disease, but also by more intensive and sustained care per patient over time.
Indirect losses are no longer a side calculation
The analysis did not stop at hospital bills. It also modeled tax losses linked to morbidity and mortality, absenteeism, caregiver productivity losses, and excess sick leave and disability costs. Those components are easy to overlook when policy discussions focus narrowly on reimbursement, yet they are central to how chronic cancer reshapes a national economy.
For working-age patients, multiple myeloma can interrupt employment through fatigue, pain, recurrent infections, anemia, fractures, and treatment-related toxicity. In practical terms, every lost week of work reduces taxable income and shifts costs into social insurance or informal care. Caregivers absorb additional productivity losses when family members step away from paid work to accompany patients to treatment, manage symptoms, or provide day-to-day support.
The abstract does not provide separate line-item values for each indirect category, but the direction of travel is clear: productivity losses are becoming a more visible contributor to the total fiscal burden. In a system like Croatia’s, that means the health impact of the disease cannot be judged by drug expenditure alone. A therapy that extends life but preserves function may create savings beyond the hospital, even if the medication price appears high at the point of purchase.
Why reimbursement policy now has to look wider than pharmacy spending
The conclusion is direct: policies that improve timely access to effective therapies, support caregivers, and maintain workforce attachment could generate modest but measurable fiscal benefits. That is not a vague appeal for spending more. It is an argument that the timing and quality of treatment can influence where costs land across society.
When effective therapy reaches patients earlier, it may reduce the cascade of complications that lead to hospitalization, disability, and long absences from work. Better disease control can also delay the functional decline that forces patients out of the labor force and increases reliance on informal caregiving. In economic terms, the disease burden becomes partly a function of whether the patient remains connected to work and community life, not only whether the health service can cover the next infusion, prescription, or admission.
The analysis supports a “whole-of-government” approach because fiscal consequences are distributed across public accounts. Health insurance pays the direct bill, but tax authorities lose revenue when patients and caregivers withdraw from work, and social systems shoulder more disability and sick leave costs. A reimbursement framework that ignores those downstream effects risks underestimating the value of interventions that preserve function.
A linear projection still leaves policy with a narrow window
The projected increase to €60.30 million by 2030 is based on linear extrapolation, so it reflects continuity rather than disruption. That method is useful for planning, but it also means the estimate assumes no major shift in incidence, survival, treatment patterns, or labor-force participation. Real-world changes in access to newer regimens, supportive care, or survivorship support could bend the curve in either direction.
Even with that caution, the direction of the trend is unmistakable. Croatia’s fiscal burden from multiple myeloma has more than quadrupled over 15 years, and the cost base is increasingly concentrated in direct health care spending while indirect losses remain important. For clinicians and health economists, the message is the same: the disease’s impact is now measured in clinic visits, but also in payrolls, disability systems, and the quiet economic toll on families.
The study does not answer which treatment mix would be most cost-efficient for Croatia, nor does it assign fiscal value to individual therapies. What it does establish is that policy decisions built only around medical invoices miss a substantial part of the burden, especially as patients live longer and remain in the care system for more years.